Hepato Cellular Carcinoma (HCC) Clinical Trials

9 recruiting

Frequently Asked Questions

Common questions about Hepato Cellular Carcinoma (HCC) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting
Not Applicable

Outpatient Versus Inpatient Care Pathway for Intra-arterial Treatment of Primary Liver Cancer (CHOC)

Intrahepatic CholangiocarcinomaHepato Cellular Carcinoma (HCC)
University Hospital, Angers206 enrolled14 locationsNCT06990659
Recruiting
Phase 2Phase 3

Transarterial Chemoembolization (TACE) Plus ABCB1 Inhibition Versus TACE Alone in Patients With Hepatocellular Carcinoma

Hepato Cellular Carcinoma (HCC)
University Hospital, Basel, Switzerland152 enrolled3 locationsNCT07302919
Recruiting
Phase 3

Camrelizumab and Apatinib With or Without FOLFOX Chemotherapy for Advanced HCC

Chemotherapy EffectHepato Cellular Carcinoma (HCC)
Linhui Peng326 enrolled1 locationNCT07267806
Recruiting

Hepatocellular Carcinoma Identification Using Delta-HLD

Hepato Cellular Carcinoma (HCC)
Epiliquid Holding, Inc200 enrolled1 locationNCT07148310
Recruiting

Effect and Mechanism of ALPPS Operation on Liver Regeneration

Liver CancerHepatobiliary CancersLiver Regeneration+1 more
Haitao Zhao, MD50 enrolled1 locationNCT07142213
Recruiting

PIVKA-II for Predicting Portal Vein Thrombosis in Hepatocellular Carcinoma

Hepato Cellular Carcinoma (HCC)Portal Vein Tumour Thrombosis
Tanta University116 enrolled1 locationNCT06960954
Recruiting

Fibroscan Evaluating Immunotherapy Response in Hepatocellular Carcinoma

Hepato Cellular Carcinoma (HCC)
Tanta University80 enrolled1 locationNCT06960863
Recruiting
Phase 2

HAIC Combined with Donafenib and Sintilimab As Perioperative Treatment for Resectable Hepatocellular Carcinoma Patients At High Risk of Recurrence

Hepato Cellular Carcinoma (HCC)
Fudan University165 enrolled3 locationsNCT06812039
Recruiting
Phase 2

PD-L1 Antibody + Bevacizumab With Hepatic Arterial Infusion Chemotherapy for Advanced HCC

Hepato Cellular Carcinoma (HCC)
West China Hospital36 enrolled1 locationNCT06742424